Presentation on Research Findings, Recognitions, Clinical Trial Results, and Orphan Drug Designations - Research Report on

 Presentation on Research Findings, Recognitions, Clinical Trial Results, and
  Orphan Drug Designations - Research Report on Celgene, Biogen Idec, Amgen,
                             Nektar, and Zalicus

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, October 2, 2013

NEW YORK, October 2, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Celgene
Corporation (NASDAQ: CELG), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc.
(NASDAQ: AMGN), Nektar Therapeutics (NASDAQ: NKTR), and Zalicus Inc. (NASDAQ:
ZLCS). Today's readers may access these reports free of charge - including
full price targets, industry analysis and analyst ratings - via the links
below.

Celgene Corporation Research Report 

On September 26, 2013, Celgene Corporation's subsidiary, Celgene International
Sarl (Celgene International) announced that its will present the latest
research findings on apremilast, an oral small-molecule selective inhibitor of
phosphodiesterase 4 (PDE4), at the 2013 American College of Rheumatology
(ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting,
to be held from October 25 to October 31, 2013 in San Diego. The Company
informed that the data to be presented include the long-term results from two
Phase III investigational trials, evaluating the treatment with apremilast for
patients with psoriatic arthritis (PALACE 2), as well as in patients with
psoriatic arthritis with skin involvement (PALACE 3). Further, Celgene
International stated that the results from BCT-0001, a Phase II trial,
evaluating apremilast in patients with Behcet's Disease with active oral
ulcers will also be presented. The Full Research Report on Celgene Corporation
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-29/CELG]

Biogen Idec Inc. Research Report

On September 24, 2013, Biogen Idec Inc. (Biogen Idec) announced that it has
been named into the Dow Jones Sustainability World Index (DJSI World). The
Company stated that the recognition makes Biogen Idec the first and only
US-based biotech sector firm to be included in the list. The Company also
informed that it has been named to the DJSI North America for the fourth
consecutive year. Further, the Company stated that it has bagged the top
Carbon Disclosure Score for the biotech sector in Carbon Disclosure Project's
(CDP) Annual Investor Survey. The Full Research Report on Biogen Idec Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-29/BIIB]

Amgen, Inc. Research Report

On September 28, 2013, Amgen, Inc. (Amgen) announced the results from the
Phase 3 ASPECCT ('763) trial, which compared Vectibix (panitumumab) to Erbitux
(cetuximab) for the treatment of wild-type KRAS metastatic colorectal cancer
in patients who have not responded to chemotherapy. According to the Company,
the study has met its primary endpoint, demonstrating that panitumumab was
non-inferior to cetuximab for overall survival. Sean E. Harper, M.D.,
Executive Vice President of Research and Development at Amgen said, "ASPECCT
was a well-conducted and robust Phase 3 trial involving nearly 1,000 patients
globally with metastatic colorectal cancer, Colorectal cancer is a devastating
disease and these results provide physicians with important new information
about the role Vectibix can play as they evaluate treatment options." The Full
Research Report on Amgen, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-29/AMGN]

Nektar Therapeutics Research Report

On September 26, 2013, Nektar Therapeutics (Nektar) reported the preliminary
topline results from a Phase 2 study of NKTR-181 for the treatment of
moderate-to-severe chronic pain in patients with osteoarthritis of the knee.
According to the Company, only 9 (3%) out of the 295 patients under study,
were unable to achieve meaningful pain relief with NKTR-181, while 53 (18%)
patients discontinued treatment during the titration period because of adverse
events, while a total of 213 patients achieved an average 40% reduction in
pain and entered the randomized phase of the study. "We were very pleased that
this drug clearly performs as an effective analgesic with only 3% of the
patients who received NKTR-181 unable to titrate to meaningful pain relief,"
said Howard W. Robin, President and CEO of Nektar. "We are carefully
evaluating the lack of post-randomization rebound in the placebo arm in order
to design the optimal pivotal trials for this drug. Based upon the data from
this trial, it is clear that NKTR-181 provides pain relief on par with
existing opioids while achieving a very favorable safety profile that
differentiates it from standard opioids." The Full Research Report on Nektar
Therapeutics - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-29/NKTR]

Zalicus Inc. Research Report 

On September 27, 2013, Zalicus Inc. (Zalicus) announced that Z160, the
Company's first-in-class, oral, state-dependent, selective N-type calcium
channel modulator in development for chronic neuropathic pain, has received
Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for
the management of postherpetic neuralgia. "The FDA's designation of Z160 as
having orphan drug status is an important milestone for Zalicus as we continue
the clinical development work required for potential FDA approval of Z160,"
commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. Zalicus also
informed that it had completed patient enrollment in two Phase 2 clinical
studies of Z160 for chronic neuropathic pain indications including
postherpetic neuralgia and lumbosacral radiculopathy on September 3, 2013.The
Company added that the top-line results of both studies are expected in Q4
2013.The Full Research Report on Zalicus Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.investorsreports.com/report/2013-09-29/ZLCS]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

www.InvestorsReports.com

SOURCE Investors' Reports

Contact: Kristi Saunders, +1-315-982-6420 (North America)